JP2019525915A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019525915A5 JP2019525915A5 JP2019500509A JP2019500509A JP2019525915A5 JP 2019525915 A5 JP2019525915 A5 JP 2019525915A5 JP 2019500509 A JP2019500509 A JP 2019500509A JP 2019500509 A JP2019500509 A JP 2019500509A JP 2019525915 A5 JP2019525915 A5 JP 2019525915A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pulmonary
- hypertension
- disorders
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 15
- 208000035475 disorder Diseases 0.000 claims 11
- 208000002815 pulmonary hypertension Diseases 0.000 claims 9
- 208000006011 Stroke Diseases 0.000 claims 7
- 230000001154 acute effect Effects 0.000 claims 7
- 230000002685 pulmonary effect Effects 0.000 claims 7
- 206010012289 Dementia Diseases 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 206010019280 Heart failures Diseases 0.000 claims 5
- 206010020772 Hypertension Diseases 0.000 claims 5
- 208000001647 Renal Insufficiency Diseases 0.000 claims 5
- 230000001684 chronic effect Effects 0.000 claims 5
- 210000002216 heart Anatomy 0.000 claims 5
- 201000006370 kidney failure Diseases 0.000 claims 5
- 208000004296 neuralgia Diseases 0.000 claims 5
- 208000021722 neuropathic pain Diseases 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- 208000031229 Cardiomyopathies Diseases 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 4
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 4
- 150000001768 cations Chemical class 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 4
- 230000006378 damage Effects 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 4
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 230000002093 peripheral effect Effects 0.000 claims 4
- 201000011461 pre-eclampsia Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 230000002792 vascular Effects 0.000 claims 4
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 3
- 206010003694 Atrophy Diseases 0.000 claims 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 3
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 3
- 208000006029 Cardiomegaly Diseases 0.000 claims 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims 3
- 206010014561 Emphysema Diseases 0.000 claims 3
- 206010019196 Head injury Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 3
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 3
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 3
- 208000033626 Renal failure acute Diseases 0.000 claims 3
- 230000037444 atrophy Effects 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 230000003511 endothelial effect Effects 0.000 claims 3
- 208000010706 fatty liver disease Diseases 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 208000028867 ischemia Diseases 0.000 claims 3
- 208000017169 kidney disease Diseases 0.000 claims 3
- 210000004072 lung Anatomy 0.000 claims 3
- 208000030159 metabolic disease Diseases 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 230000000414 obstructive effect Effects 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 206010003671 Atrioventricular Block Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010006482 Bronchospasm Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010011796 Cystitis interstitial Diseases 0.000 claims 2
- 206010013496 Disturbance in attention Diseases 0.000 claims 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 2
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 2
- 208000005189 Embolism Diseases 0.000 claims 2
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 108010028554 LDL Cholesterol Proteins 0.000 claims 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 206010027525 Microalbuminuria Diseases 0.000 claims 2
- 208000034486 Multi-organ failure Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010063985 Phytosterolaemia Diseases 0.000 claims 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims 2
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims 2
- 201000001068 Prinzmetal angina Diseases 0.000 claims 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 2
- 208000003782 Raynaud disease Diseases 0.000 claims 2
- 208000002227 Sitosterolemia Diseases 0.000 claims 2
- 208000001435 Thromboembolism Diseases 0.000 claims 2
- 208000032594 Vascular Remodeling Diseases 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- 208000009729 Ventricular Premature Complexes Diseases 0.000 claims 2
- 206010065341 Ventricular tachyarrhythmia Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 201000011040 acute kidney failure Diseases 0.000 claims 2
- 125000002723 alicyclic group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 238000002399 angioplasty Methods 0.000 claims 2
- 206010002906 aortic stenosis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000001746 atrial effect Effects 0.000 claims 2
- 230000007885 bronchoconstriction Effects 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 229940109239 creatinine Drugs 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 238000000502 dialysis Methods 0.000 claims 2
- 230000003205 diastolic effect Effects 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000007232 portal hypertension Diseases 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- 210000001147 pulmonary artery Anatomy 0.000 claims 2
- 230000009467 reduction Effects 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- 206010047302 ventricular tachycardia Diseases 0.000 claims 2
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010001580 Albuminuria Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 206010002199 Anaphylactic shock Diseases 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010002915 Aortic valve incompetence Diseases 0.000 claims 1
- 206010003130 Arrhythmia supraventricular Diseases 0.000 claims 1
- 200000000007 Arterial disease Diseases 0.000 claims 1
- 206010003175 Arterial spasm Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 208000002102 Atrial Premature Complexes Diseases 0.000 claims 1
- 206010003662 Atrial flutter Diseases 0.000 claims 1
- 208000006808 Atrioventricular Nodal Reentry Tachycardia Diseases 0.000 claims 1
- 206010061666 Autonomic neuropathy Diseases 0.000 claims 1
- 201000006935 Becker muscular dystrophy Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010071445 Bladder outlet obstruction Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000004990 Cardiorenal syndrome Diseases 0.000 claims 1
- 206010048610 Cardiotoxicity Diseases 0.000 claims 1
- 206010059109 Cerebral vasoconstriction Diseases 0.000 claims 1
- 208000026151 Chronic thromboembolic pulmonary hypertension Diseases 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 208000029147 Collagen-vascular disease Diseases 0.000 claims 1
- 208000014526 Conduction disease Diseases 0.000 claims 1
- 208000002330 Congenital Heart Defects Diseases 0.000 claims 1
- 208000004117 Congenital Myasthenic Syndromes Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 208000019886 Congenital renal disease Diseases 0.000 claims 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 claims 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 208000007530 Essential hypertension Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000021663 Female sexual arousal disease Diseases 0.000 claims 1
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 1
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 206010070538 Gestational hypertension Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 1
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020575 Hyperammonaemia Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020852 Hypertonia Diseases 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 206010021036 Hyponatraemia Diseases 0.000 claims 1
- 206010058558 Hypoperfusion Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010021133 Hypoventilation Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 claims 1
- 208000006264 Korsakoff syndrome Diseases 0.000 claims 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
- 206010024119 Left ventricular failure Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000008771 Lymphadenopathy Diseases 0.000 claims 1
- 206010025219 Lymphangioma Diseases 0.000 claims 1
- 208000002805 Mediastinal fibrosis Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000011682 Mitral valve disease Diseases 0.000 claims 1
- 206010027727 Mitral valve incompetence Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000002038 Muscle Hypertonia Diseases 0.000 claims 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 1
- 206010029279 Neurogenic bladder Diseases 0.000 claims 1
- 208000007125 Neurotoxicity Syndromes Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000036576 Obstructive uropathy Diseases 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 206010034487 Pericarditis constrictive Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 206010061340 Peripheral embolism Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 208000008601 Polycythemia Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 claims 1
- 208000031467 Pulmonary capillary hemangiomatosis Diseases 0.000 claims 1
- 206010037423 Pulmonary oedema Diseases 0.000 claims 1
- 206010037457 Pulmonary vasculitis Diseases 0.000 claims 1
- 208000014777 Pulmonary venoocclusive disease Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 201000007981 Reye syndrome Diseases 0.000 claims 1
- 206010039163 Right ventricular failure Diseases 0.000 claims 1
- 201000004239 Secondary hypertension Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 1
- 208000003734 Supraventricular Tachycardia Diseases 0.000 claims 1
- 206010071436 Systolic dysfunction Diseases 0.000 claims 1
- 208000001871 Tachycardia Diseases 0.000 claims 1
- 208000001163 Tangier disease Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000018452 Torsade de pointes Diseases 0.000 claims 1
- 208000002363 Torsades de Pointes Diseases 0.000 claims 1
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 1
- 231100000076 Toxic encephalopathy Toxicity 0.000 claims 1
- 206010060872 Transplant failure Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 201000001943 Tricuspid Valve Insufficiency Diseases 0.000 claims 1
- 206010044640 Tricuspid valve incompetence Diseases 0.000 claims 1
- 206010044642 Tricuspid valve stenosis Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 claims 1
- 206010046914 Vaginal infection Diseases 0.000 claims 1
- 201000008100 Vaginitis Diseases 0.000 claims 1
- 208000009325 Variant Angina Pectoris Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 208000008131 Ventricular Flutter Diseases 0.000 claims 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims 1
- 201000008803 Wolff-Parkinson-white syndrome Diseases 0.000 claims 1
- 206010048215 Xanthomatosis Diseases 0.000 claims 1
- 230000035508 accumulation Effects 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 208000013228 adenopathy Diseases 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 208000033571 alveolar capillary dysplasia with misalignment of pulmonary veins Diseases 0.000 claims 1
- -1 amine compound Chemical class 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 201000002064 aortic valve insufficiency Diseases 0.000 claims 1
- 230000037007 arousal Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 208000037849 arterial hypertension Diseases 0.000 claims 1
- 210000002565 arteriole Anatomy 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 230000036765 blood level Effects 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 206010007625 cardiogenic shock Diseases 0.000 claims 1
- 231100000259 cardiotoxicity Toxicity 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 230000003788 cerebral perfusion Effects 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 208000028831 congenital heart disease Diseases 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 208000000839 constrictive pericarditis Diseases 0.000 claims 1
- 238000007887 coronary angioplasty Methods 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 201000009101 diabetic angiopathy Diseases 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- 230000008694 endothelial dysfunction Effects 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 229940012952 fibrinogen Drugs 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 210000001652 frontal lobe Anatomy 0.000 claims 1
- 230000001434 glomerular Effects 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- 230000036541 health Effects 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 208000007386 hepatic encephalopathy Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 201000005991 hyperphosphatemia Diseases 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 208000018875 hypoxemia Diseases 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 208000001286 intracranial vasospasm Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 230000028252 learning or memory Effects 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 201000002818 limb ischemia Diseases 0.000 claims 1
- 230000006372 lipid accumulation Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000003141 lower extremity Anatomy 0.000 claims 1
- 206010025005 lumbar spinal stenosis Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 201000001231 mediastinitis Diseases 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 208000006887 mitral valve stenosis Diseases 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 230000004112 neuroprotection Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000020629 overactive bladder Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000008447 perception Effects 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 230000036316 preload Effects 0.000 claims 1
- 206010036596 premature ejaculation Diseases 0.000 claims 1
- 238000004321 preservation Methods 0.000 claims 1
- 208000037920 primary disease Diseases 0.000 claims 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000005333 pulmonary edema Diseases 0.000 claims 1
- 201000010298 pulmonary valve insufficiency Diseases 0.000 claims 1
- 208000009138 pulmonary valve stenosis Diseases 0.000 claims 1
- 208000037813 pulmonary venous hypertension Diseases 0.000 claims 1
- 208000030390 pulmonic stenosis Diseases 0.000 claims 1
- 230000010451 regulation of platelet aggregation Effects 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 208000015658 resistant hypertension Diseases 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 201000004409 schistosomiasis Diseases 0.000 claims 1
- 208000037812 secondary pulmonary hypertension Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000036299 sexual function Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 208000005198 spinal stenosis Diseases 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 210000004003 subcutaneous fat Anatomy 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 206010042772 syncope Diseases 0.000 claims 1
- 230000006794 tachycardia Effects 0.000 claims 1
- 230000000542 thalamic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000002537 thrombolytic effect Effects 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 201000002327 urinary tract obstruction Diseases 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 208000003663 ventricular fibrillation Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022010212A JP7368516B2 (ja) | 2016-07-07 | 2022-01-26 | ｓＧＣ刺激剤のリンプロドラッグ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359419P | 2016-07-07 | 2016-07-07 | |
| US62/359,419 | 2016-07-07 | ||
| PCT/US2017/040809 WO2018009596A1 (en) | 2016-07-07 | 2017-07-06 | Phosphorus prodrugs of sgc stimulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022010212A Division JP7368516B2 (ja) | 2016-07-07 | 2022-01-26 | ｓＧＣ刺激剤のリンプロドラッグ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019525915A JP2019525915A (ja) | 2019-09-12 |
| JP2019525915A5 true JP2019525915A5 (enExample) | 2020-08-13 |
| JP7016853B2 JP7016853B2 (ja) | 2022-02-07 |
Family
ID=59351139
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019500509A Active JP7016853B2 (ja) | 2016-07-07 | 2017-07-06 | ｓＧＣ刺激剤のリンプロドラッグ |
| JP2022010212A Active JP7368516B2 (ja) | 2016-07-07 | 2022-01-26 | ｓＧＣ刺激剤のリンプロドラッグ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022010212A Active JP7368516B2 (ja) | 2016-07-07 | 2022-01-26 | ｓＧＣ刺激剤のリンプロドラッグ |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10927136B2 (enExample) |
| EP (1) | EP3481837B1 (enExample) |
| JP (2) | JP7016853B2 (enExample) |
| KR (1) | KR102513343B1 (enExample) |
| CN (2) | CN114736240A (enExample) |
| AU (2) | AU2017291826B2 (enExample) |
| BR (1) | BR112019000290B1 (enExample) |
| CA (1) | CA3029374A1 (enExample) |
| EA (1) | EA039683B1 (enExample) |
| IL (1) | IL263993B2 (enExample) |
| MA (1) | MA45592A (enExample) |
| MX (2) | MX391896B (enExample) |
| WO (1) | WO2018009596A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX391896B (es) * | 2016-07-07 | 2025-03-21 | Cyclerion Therapeutics Inc | Profármacos de fósforo de estimuladores de guanilato ciclasa soluble (sgc). |
| JP7542518B2 (ja) | 2018-07-11 | 2024-08-30 | ティセント セラピューティクス インコーポレーテッド | ミトコンドリア（ｍｉｔｏｃｈｏｎｒｉａｌ）障害の処置のためのｓＧＣ刺激剤の使用 |
| CN114377149B (zh) * | 2021-12-14 | 2023-11-10 | 西北工业大学 | 一种Mn基可降解MOF纳米反应器及其制备方法和应用 |
| WO2024102304A1 (en) * | 2022-11-07 | 2024-05-16 | Virginia Commonwealth University | Benzaldehyde compounds with direct polymer destabilizing effects to treat sickle cell disease |
| CN116478309B (zh) * | 2023-05-19 | 2024-05-17 | 青海大学 | 锁阳精多糖、锁阳多糖化合物及制备方法和应用 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721365A (en) | 1989-09-15 | 1998-02-24 | Us Health | N-substituted piperazine NONOates |
| US5366997A (en) | 1991-09-24 | 1994-11-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs |
| US5155137A (en) | 1990-09-20 | 1992-10-13 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Complexes of nitric oxide with polyamines |
| US5814666A (en) | 1992-04-13 | 1998-09-29 | The United States As Represented By The Department Of Health And Human Services | Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents |
| US5691423A (en) | 1992-08-24 | 1997-11-25 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-bound nitric oxide-nucleophile adducts |
| US5405919A (en) | 1992-08-24 | 1995-04-11 | The United States Of America As Represented By The Secretary Of Health And Human Services | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders |
| US5632981A (en) | 1992-08-24 | 1997-05-27 | The United States Of America As Represented By The Department Of Health And Human Services | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
| US5910316A (en) | 1992-08-24 | 1999-06-08 | The United States Of America, As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents to treat impotency |
| US5650442A (en) | 1993-10-08 | 1997-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Use of nitric oxide releasing compounds as hypoxic cell radiation sensitizers |
| JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| US5700830A (en) | 1994-11-22 | 1997-12-23 | The United States Of America As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents for reducing metastasis risk |
| DK0837052T3 (da) | 1995-06-21 | 2007-01-02 | Shionogi & Co | Bicykliske aminoderivater og PGD2-antagonist indeholdende disse |
| US5714511A (en) | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
| WO1998025915A1 (en) | 1996-12-12 | 1998-06-18 | Shionogi & Co., Ltd. | Fused heterocyclic benzenecarboxylic acid amide derivatives and pgd2 antagonists containing the same |
| US6083974A (en) | 1996-12-13 | 2000-07-04 | Shionogi & Co., Ltd. | Benzothiophenecarboxamide derivatives and PGD2 antagonists comprising them |
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| DE19830430A1 (de) | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| BR9911914B1 (pt) | 1998-07-08 | 2010-10-19 | n-arilamidas do ácido sulfonilaminocarboxìlico substituìdas por enxofre, processo para sua preparação, bem como preparações farmacêuticas que compreendem as mesmas. | |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| US20010051624A1 (en) | 2000-04-12 | 2001-12-13 | Jones Thomas R. | Method and compositions for the treatment of allergic conditions using PGD2 receptor antagonists |
| JP2003530426A (ja) | 2000-04-12 | 2003-10-14 | メルク フロスト カナダ アンド カンパニー | Ｐｇｄ２受容体拮抗薬を用いるアレルギー状態の治療のための方法および組成物 |
| US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| PE20020870A1 (es) | 2001-02-13 | 2002-11-18 | Aventis Pharma Gmbh | 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas |
| TWI241190B (en) | 2001-02-13 | 2005-10-11 | Aventis Pharma Gmbh | 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical |
| PE20020856A1 (es) | 2001-02-13 | 2002-11-11 | Aventis Pharma Gmbh | 1,2,3,4-tetrahidronaftil aminas aciladas |
| US6511911B1 (en) | 2001-04-03 | 2003-01-28 | Advanced Micro Devices, Inc. | Metal gate stack with etch stop layer |
| CA2459515A1 (en) | 2001-09-07 | 2003-03-20 | Kazuhiko Torisu | Indole derivatives |
| US7153852B2 (en) | 2001-09-07 | 2006-12-26 | Ono Pharmaceutical Co., Ltd. | Indole compounds, process for producing the same and drugs containing the same as the active ingredient |
| SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| AU2003231509A1 (en) | 2002-05-16 | 2003-12-02 | Shionogi And Co., Ltd. | Compound exhibiting pgd 2 receptor antagonism |
| JPWO2003097042A1 (ja) | 2002-05-16 | 2005-09-15 | 塩野義製薬株式会社 | Ｐｇｄ２受容体拮抗剤 |
| SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| EP1556047A4 (en) | 2002-10-04 | 2009-09-30 | Millennium Pharm Inc | ANTAGONISTS AGAINST THE PGD2 RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES |
| ES2401079T3 (es) | 2002-12-20 | 2013-04-16 | Amgen Inc. | Moduladores del asma y de la inflamación alérgica |
| US8309608B2 (en) | 2003-11-06 | 2012-11-13 | Sanofi-Aventis Deutschland Gmbh | Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases |
| ES2533007T3 (es) * | 2005-12-27 | 2015-04-06 | Otsuka Pharmaceutical Co., Ltd. | Compuesto de benzoacepina soluble en agua y su composición farmacéutica |
| DE102007036075A1 (de) * | 2007-08-01 | 2009-02-05 | Bayer Healthcare Ag | Prodrugs und ihre Verwendung |
| BRPI0816382A2 (pt) | 2007-09-06 | 2015-02-24 | Merck Sharp & Dohme | Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças |
| EP2244575B1 (en) | 2008-01-24 | 2013-07-17 | Merck Sharp & Dohme Corp. | Angiotensin ii receptor antagonists |
| CN101735267A (zh) * | 2008-11-17 | 2010-06-16 | 上海阳帆医药科技有限公司 | 水溶性(r)-(-)-比卡鲁胺前药、其制备方法及用途 |
| EP2373317B1 (en) | 2008-11-25 | 2016-12-14 | Merck Sharp & Dohme Corp. | 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases |
| JP5411300B2 (ja) | 2009-02-26 | 2014-02-12 | メルク・シャープ・アンド・ドーム・コーポレーション | 可溶性グアニレートシクラーゼ活性化剤 |
| WO2011119518A1 (en) | 2010-03-25 | 2011-09-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| CA2800541C (en) | 2010-05-27 | 2016-03-22 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| US8895583B2 (en) | 2010-10-28 | 2014-11-25 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| AU2012205415B2 (en) * | 2011-01-14 | 2017-02-02 | Spero Therapeutics, Inc. | Pyrimidine gyrase and topoisomerase IV inhibitors |
| CN103288809B (zh) * | 2012-02-24 | 2015-09-23 | 深圳市健元医药科技有限公司 | 葛根素单磷酸盐或单磺酸盐衍生物及其制备方法 |
| IL285564B2 (en) * | 2013-03-15 | 2024-06-01 | Cyclerion Therapeutics Inc | sGC Stimulators |
| BR112015025033B1 (pt) * | 2013-03-29 | 2022-04-19 | Xuanzhu Pharma Co., Ltd | Composto e seu uso como inibidor de pde-5, bem como preparação farmacêutica compreeendendo o dito composto |
| EP3094327A1 (en) * | 2014-01-13 | 2016-11-23 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
| MX391896B (es) * | 2016-07-07 | 2025-03-21 | Cyclerion Therapeutics Inc | Profármacos de fósforo de estimuladores de guanilato ciclasa soluble (sgc). |
-
2017
- 2017-07-06 MX MX2019000103A patent/MX391896B/es unknown
- 2017-07-06 JP JP2019500509A patent/JP7016853B2/ja active Active
- 2017-07-06 BR BR112019000290-1A patent/BR112019000290B1/pt active IP Right Grant
- 2017-07-06 US US16/315,210 patent/US10927136B2/en active Active
- 2017-07-06 KR KR1020197003458A patent/KR102513343B1/ko active Active
- 2017-07-06 CN CN202111570967.XA patent/CN114736240A/zh active Pending
- 2017-07-06 CN CN201780045937.2A patent/CN109476686B/zh active Active
- 2017-07-06 WO PCT/US2017/040809 patent/WO2018009596A1/en not_active Ceased
- 2017-07-06 MA MA045592A patent/MA45592A/fr unknown
- 2017-07-06 AU AU2017291826A patent/AU2017291826B2/en active Active
- 2017-07-06 EA EA201990238A patent/EA039683B1/ru unknown
- 2017-07-06 EP EP17740237.7A patent/EP3481837B1/en active Active
- 2017-07-06 CA CA3029374A patent/CA3029374A1/en active Pending
-
2018
- 2018-12-27 IL IL263993A patent/IL263993B2/en unknown
-
2019
- 2019-01-07 MX MX2022005024A patent/MX2022005024A/es unknown
-
2022
- 2022-01-19 AU AU2022200331A patent/AU2022200331B2/en active Active
- 2022-01-26 JP JP2022010212A patent/JP7368516B2/ja active Active
-
2023
- 2023-09-01 US US18/241,630 patent/US20240228520A9/en not_active Abandoned
-
2024
- 2024-01-12 US US18/411,480 patent/US20240360164A1/en not_active Abandoned
- 2024-11-14 US US18/947,131 patent/US20250243228A1/en active Pending